.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,138,375

« Back to Dashboard

Details for Patent: 7,138,375

Title:Use of exendins and agonists thereof for lowering plasma lipid
Abstract: Provided are methods for lowering plasma lipid in an individual in need of or desirous of lowering plasma lipid by administering an amount of an exendin or an exendin agonist analog effective to lower plasma lipid.
Inventor(s): Beeley; Nigel Robert Arnold (Solana Beach, CA), Prickett; Kathryn S. (San Diego, CA), Bhavsar; Sunil (San Diego, CA), Young; Andrew (La Jolla, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:Oct 14, 2004
Application Number:10/966,337
Claims:1. A method for lowering a plasma lipid in a subject comprising peripherally administering to a subject desirous or in need of lowering a plasma lipid an amount of an exendin or an exendin agonist analog effective to lower a plasma lipid.

2. The method of claim 1, wherein said administration is by injection.

3. The method of claim 1, wherein said administration is selected from the group consisting of intravenous administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, oral administration, topical administration, transmucosal administration, and pulmonary administration.

4. The method of claim 1, wherein said exendin is an exendin-3 or an exendin-4.

5. The method of claim 1, wherein said exendin is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, .sup.14Leu, .sup.25Phe exendin-4 amide, .sup.14Leu, .sup.25Phe exendin-4 (1-28) amide, and .sup.14Leu, .sup.22Ala, .sup.25Phe exendin-4 (1-28) amide.

6. The method of claim 1, wherein said exendin or exendin agonist analog comprises any one of the amino acid sequences selected from the group consisting of SEQ ID NO:9 to SEQ ID NO:188.

7. The method of claim 1, wherein said exendin or exendin agonist analog has an amino acid sequence comprising: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Gly Thr Xaa.sub.4 Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 Ser Lys Gln Xaa.sub.9 Glu Glu Glu Ala Val Arg Leu Xaa.sub.10 Xaa.sub.11 Xaa.sub.12 Xaa.sub.13 Leu Lys Asn Gly Gly Xaa.sub.14 Ser Ser Gly Ala Xaa.sub.15 Xaa.sub.16 Xaa.sub.17 Xaa.sub.18-Z [SEQ ID NO. 3] wherein Xaa.sub.1 is His, Arg or Tyr; Xaa.sub.2 is Ser, Gly, Ala or Thr; Xaa.sub.3 is Asp or Glu; Xaa.sub.4 is Phe, Tyr or naphthylalanine; Xaa.sub.5 is Thr or Ser; Xaa.sub.6 is Ser or Thr; Xaa.sub.7 is Asp or Glu; Xaa.sub.8 is Leu, Ile, Val, pentylglycine or Met; Xaa.sub.9 is Leu, Ile, pentylglycine, Val or Met; Xaa.sub.10 is Phe, Tyr or naphthylalanine; Xaa.sub.11 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa.sub.12 is Glu or Asp; Xaa.sub.13 is Trp, Phe, Tyr, or naphthylalanine; Xaa.sub.14, Xaa.sub.15, Xaa.sub.16 and Xaa.sub.17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa.sub.18 is Ser, Thr or Tyr; and Z is --OH or --NH.sub.2.

8. The method of claim 1, wherein said exendin or exendin agonist analog has an amino acid sequence comprising: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Gly Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 Xaa.sub.9 Xaa.sub.10 Xaa.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Xaa.sub.15 Xaa.sub.16 Xaa.sub.17 Ala Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 Xaa.sub.22 Xaa.sub.23 Xaa.sub.24 Xaa.sub.25 Xaa.sub.26 Xaa.sub.27 Xaa.sub.28-Z.sub.1 [SEQ ID NO:4] wherein Xaa.sub.1 is His, Arg or Tyr; Xaa.sub.2 is Ser, Gly, Ala or Thr; Xaa.sub.3 is Ala Asp or Glu; Xaa.sub.5 is Ala or Thr; Xaa.sub.6 is Ala, Phe, Tyr or naphthylalanine; Xaa.sub.7 is Thr or Ser; Xaa.sub.8 is Ala, Ser or Thr; Xaa.sub.9 is Asp or Glu; Xaa.sub.10 is Ala, Leu, Ile, Val, pentylglycine or Met; Xaa.sub.11 is Ala or Ser; Xaa.sub.12 is Ala or Lys; Xaa.sub.13 is Ala or Gln; Xaa.sub.14 is Ala, Leu, Ile, pentylglycine, Val or Met; Xaa.sub.15 is Ala or Glu; Xaa.sub.16 is Ala or Glu; Xaa.sub.17 is Ala or Glu; Xaa.sub.19 is Ala or Val; Xaa.sub.20 is Ala or Arg; Xaa.sub.21 is Ala or Leu; Xaa.sub.22 is Ala, Phe, Tyr or naphthylalanine; Xaa.sub.23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa.sub.24 is Ala, Glu or Asp; Xaa.sub.25 is Ala, Trp, Phe, Tyr or naphthylalanine; Xaa.sub.26 is Ala or Leu; Xaa.sub.27 is Ala or Lys; Xaa.sub.28 is Ala or Asn; Z.sub.1 is --OH, --NH.sub.2, Gly-Z.sub.2, Gly Gly-Z.sub.2, Gly Gly Xaa.sub.31-Z.sub.2, Gly Gly Xaa.sub.31 Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37-Z.sub.2 or Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37 Xaa.sub.38-Z.sub.2; wherein Xaa.sub.31, Xaa.sub.36, Xaa.sub.37 and Xaa.sub.38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; and Z.sub.2 is --OH or --NH.sub.2; provided that no more than three of Xaa.sub.3, Xaa.sub.5, Xaa.sub.6, Xaa.sub.8, Xaa.sub.10, Xaa.sub.11, Xaa.sub.12, Xaa.sub.13, Xaa.sub.14, Xaa.sub.15, Xaa.sub.16, Xaa.sub.17, Xaa.sub.19, Xaa.sub.20, Xaa.sub.21, Xaa.sub.24, Xaa.sub.25, Xaa.sub.26, Xaa.sub.27 and Xaa.sub.28 are Ala.

9. The method of claim 1, wherein said exendin or exendin agonist analog has an amino acid sequence comprising: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Xaa.sub.6 Xaa.sub.7 Xaa.sub.8 Xaa.sub.9 Xaa.sub.10 Xaa.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Xaa.sub.15 Xaa.sub.16 Xaa.sub.17 Ala Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 Xaa.sub.22 Xaa.sub.23 Xaa.sub.24 Xaa.sub.25 Xaa.sub.26 Xaa.sub.27 Xaa.sub.28-Z.sub.1 [SEQ ID NO:5] wherein Xaa.sub.1 is His, Arg, Tyr, Ala, Norval, Val or Norleu; Xaa.sub.2 is Ser, Gly, Ala or Thr; Xaa.sub.3 is Ala, Asp or Glu; Xaa.sub.4 is Ala, Norval, Val, Norleu or Gly; Xaa.sub.5 is Ala or Thr; Xaa.sub.6 is Ala, Phe, Tyr or naphthylalanine; Xaa.sub.7 is Thr or Ser; Xaa.sub.8 is Ala, Ser or Thr; Xaa.sub.9 is Ala, Norval, Val, Norleu, Asp or Glu; Xaa.sub.10 is Ala, Leu, Ile, Val, pentylglycine or Met; Xaa.sub.11 is Ala or Ser; Xaa.sub.12 is Ala or Lys; Xaa.sub.13 is Ala or Gln; Xaa.sub.14 is Ala, Leu, Ile, pentylglycine, Val or Met; Xaa.sub.15 is Ala or Glu; Xaa.sub.16 is Ala or Glu; Xaa.sub.17 is Ala or Glu; Xaa.sub.19 is Ala or Val; Xaa.sub.20 is Ala or Arg; Xaa.sub.21 is Ala or Leu; Xaa.sub.22 is Phe, Tyr or naphthylalanine; Xaa.sub.23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa.sub.24 is Ala, Glu or Asp; Xaa.sub.25 is Ala, Trp, Phe, Tyr or naphthylalanine; Xaa.sub.26 is Ala or Leu; Xaa.sub.27 is Ala or Lys; Xaa.sub.28 is Ala or Asn; Z.sub.1 is --OH, --NH.sub.2, Gly-Z.sub.2, Gly Gly-Z.sub.2, Gly Gly Xaa.sub.31-Z.sub.2, Gly Gly Xaa.sub.31 Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37-Z.sub.2, Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37 Xaa.sub.38-Z.sub.2, or Gly Gly Xaa.sub.31 Ser Ser Gly Ala Xaa.sub.36 Xaa.sub.37 Xaa.sub.38 Xaa.sub.39-Z.sub.2; wherein Xaa.sub.31, Xaa.sub.36, Xaa.sub.37, and Xaa.sub.38 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa.sub.39 is Ser or Tyr; and Z.sub.2 is --OH or --NH.sub.2; provided that no more than three of Xaa.sub.3, Xaa.sub.4, Xaa.sub.5, Xaa.sub.6, Xaa.sub.8, Xaa.sub.9, Xaa.sub.10, Xaa.sub.11, Xaa.sub.12, Xaa.sub.13, Xaa.sub.14, Xaa.sub.15, Xaa.sub.16, Xaa.sub.17, Xaa.sub.19, Xaa.sub.20, Xaa.sub.21, Xaa.sub.24, Xaa.sub.25, Xaa.sub.26, Xaa.sub.27 and Xaa.sub.28 are Ala; and provided that, if Xaa.sub.1 is His, Arg or Tyr, then at least one of Xaa.sub.3, Xaa.sub.4, and Xaa.sub.9 is Ala.

10. The method of claim 1, further comprising administering a therapeutically effective amount of at least one additional plasma lipid lowering agent.

11. The method of claim 1, further comprising administering a therapeutically effective amount of compound selected from the group consisting of amylin, an amylin agonist, a leptin, a cholecystokinin (CCK), and any combination thereof.

12. The method of claim 1, wherein about 10 .mu.g/70 kg to about 5 mg/70 kg of said exendin or exendin agonist analog is administered per day in single or divided doses.

13. The method of claim 1, wherein about 10 .mu.g/70 kg to about 2 mg/70 kg of said exendin or exendin agonist analog is administered per day in single or divided doses.

14. The method of claim 1, wherein about 10 .mu.g/70 kg to about 500 .mu.g/70 kg of said exendin or exendin agonist analog is administered per day in single or divided doses.

15. The method of claim 1, wherein about 0.1 .mu.g/kg to about 100 .mu.g/kg of said exendin or exendin agonist analog is administered per day in single or divided doses.

16. The method of claim 1, wherein about 0.1 .mu.g/kg to about 10 .mu.g/kg of said exendin or exendin agonist analog is administered per day in single or divided doses.

17. The method of claim 1, wherein about 0.1 .mu.g/kg to about 1 .mu.g/kg of said exendin or exendin agonist analog is administered per day in single or divided doses.

18. The method of claim 1, wherein said subject is human.

19. The method of claim 1, wherein said subject suffers from Type II diabetes.

20. The method of claim 1, wherein said subject suffers from an insulin-resistance syndrome.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc